Pharmaceuticals
We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.
Explore our sectors
Meet our lawyers
News & insights
News: 10 JULY 2020
Allen & Overy has advised the joint sponsors on the global offering and listing of shares of Immunotech Biopharm Ltd (Immunotech Biopharm) on the Hong Kong Stock Exchange under Chapter 18A of the…
Read more
Publications: 08 JULY 2020
Pipeline gaps and digital will drive life sciences deals
Often seen as a safe haven sector in times of crisis, the life sciences have not only been centre stage during the Covid-19 coronavirus crisis but are riding it out well.
Read more
Publications: 24 JUNE 2020
Covid-19 coronavirus: How the global life sciences sector is responding to the pandemic
Our life sciences sector team reviews the steps taken by the industry and public bodies to minimise disruption to regular business activities and to promote the development and supply of medicines and…
Read more
Publications: 24 JUNE 2020
Changes to UK merger control: public health emergencies and national security
On 21 June the UK Government announced plans to introduce a new public interest consideration to the UK merger control regime: public health emergency. It also announced a proposal to expand its…
Read moreDownload our sector brochure
